Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cyclophosphamide therapy in pediatric multiple sclerosis.

Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T.

Neurology. 2009 Jun 16;72(24):2076-82. doi: 10.1212/WNL.0b013e3181a8164c. Epub 2009 May 13.

2.

Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.

Yeh EA, Weinstock-Guttman B.

Neurology. 2009 Jun 16;72(24):2064-5. doi: 10.1212/WNL.0b013e3181a92caa. Epub 2009 May 13. No abstract available.

PMID:
19439721
3.
4.
5.

Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.

Harrison DM, Gladstone DE, Hammond E, Cheng J, Jones RJ, Brodsky RA, Kerr D, McArthur JC, Kaplin A.

Mult Scler. 2012 Feb;18(2):202-9. doi: 10.1177/1352458511419701. Epub 2011 Aug 24.

6.

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.

Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, Locher E, Coyle PK.

Arch Neurol. 2006 Oct;63(10):1388-93. Epub 2006 Aug 14.

PMID:
16908728
7.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
8.

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

Zwibel HL; Copolymer-1 Treatment Study Principal Investigators.

Acta Neurol Scand. 2006 Jun;113(6):378-86.

PMID:
16674604
9.

Concepts of induction and escalation therapy in multiple sclerosis.

Rieckmann P.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S42-5. doi: 10.1016/S0022-510X(09)70012-7. Review.

PMID:
19200866
10.

Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis.

Zaffaroni M, Rizzo A, Baldini SM, Ghezzi A, Comi G.

Neurol Sci. 2008 Sep;29 Suppl 2:S230-2. doi: 10.1007/s10072-008-0946-x.

PMID:
18690501
12.

Rationale for the use of mitoxantrone in multiple sclerosis.

Edan G, Morrissey S, Le Page E.

J Neurol Sci. 2004 Aug 15;223(1):35-9. Review.

PMID:
15261558
13.

Long-term experience with induction treatment regimens in multiple sclerosis.

Le Page E, Edan G.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S46-9. doi: 10.1016/S0022-510X(09)70013-9. Review.

PMID:
19200867
14.

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.

JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.

PMID:
23420110
15.
16.

[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Edan G.

Rev Neurol (Paris). 2006 Feb;162(2):185-94. French.

PMID:
16518258
17.

Mitoxantrone for multiple sclerosis in clinical practice.

Rizvi SA, Zwibel H, Fox EJ.

Neurology. 2004 Dec 28;63(12 Suppl 6):S25-7. Review.

PMID:
15623666
18.

[Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].

Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S.

Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Serbian.

PMID:
12583309
19.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.

Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.

Mult Scler. 2008 Jun;14(5):663-70. doi: 10.1177/1352458507085759. Epub 2008 Apr 18.

PMID:
18424479
20.

Current disease-modifying treatment of multiple sclerosis.

Derwenskus J.

Mt Sinai J Med. 2011 Mar-Apr;78(2):161-75. doi: 10.1002/msj.20239. Review.

PMID:
21425262

Supplemental Content

Support Center